DelveInsight’s “Wet Age-Related Macular Degeneration (Wet AMD) Market” report provides a thorough comprehension of the Wet Age-Related Macular Degeneration, historical and forecasted epidemiology, and the wet AMD market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan]. The Wet Age-Related Macular Degeneration market report also proffers an analysis of recent Wet AMD treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Wet Age-Related Macular Degeneration (Wet AMD): An Overview
Age-related Macular Degeneration (AMD) is a leading cause of severe, irreversible blindness worldwide, profoundly affecting individuals’ quality of life. Wet AMD is a type of AMD characterized by abrupt central vision loss caused by abnormal blood vessels that bleed or leak fluid that may swell and damage the macula. Wet AMD is also referred to as neovascular AMD, accounts for roughly 10% of AMD cases, but almost 90% of AMD-related central vision loss.
Download Free Sample Report Now @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Some of the key highlights of the Wet AMD Market Report
The Wet Age-Related Macular Degeneration Market Report provides historical as well as forecasted epidemiological analysis segmented into:
Get a sample copy of this report: https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Wet Age-Related Macular Degeneration Treatment Market
Wet AMD has no cure even though an appropriate treatment could delay disease progression, avoiding the negative impact of vision loss on these patients’ quality of life. According to the most recent AMD guidelines, the intravitreal administration of antivascular endothelial growth factor agents (anti-VEGF) constitutes the standard of care for Wet AMD patients due to the promising results provided by these therapies during clinical development. Angiogenesis inhibitors, the protein that promotes blood vessel growth, work by blocking VEGF activity. The most common and effective clinical treatment for Wet AMD is anti-VEGF therapy, a periodic intravitreal injection of a chemical called an anti-VEGF. Several VEGF therapies have been approved in the market for 7MM. These include Lucentis, Eylea, Macugen, and Boevu. Avastin is also used as an “off-label” drug.
Wet AMD Companies along with drugs
Wet Age-Related Macular Degeneration Market Drivers
Visit for deep insights into the Wet Age-Related Macular Degeneration patient pool @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Wet Age-Related Macular Degeneration Market Barriers
Request for More Info @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Table of content
1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis
4. Market Overview at a Glance
5. Disease Background and Overview
6. Patient Journey
7. Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Wet Age-Related Macular Degeneration (Wet AMD) Treatment
11. Marketed Products
12. Emerging Therapies
13. Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Consult with our Business Expert @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market